{
    "Trade/Device Name(s)": [
        "ETERBIO Fentanyl/Norfentanyl Rapid Test (Colloidal Gold)",
        "ETERBIO Fentanyl/Norfentanyl Home Test"
    ],
    "Submitter Information": "Eterbio, Inc.",
    "510(k) Number": "K243064",
    "Predicate Device Reference 510(k) Number(s)": [
        "K241969"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NGL"
    ],
    "Summary Letter Date": "September 26, 2024",
    "Summary Letter Received Date": "September 27, 2024",
    "Submission Date": "October 21, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Fentanyl",
        "Norfentanyl"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunoassay",
        "Lateral flow immunochromatographic assay",
        "Colloidal gold"
    ],
    "Methodologies": [
        "Competitive binding immunoassay"
    ],
    "Submission Type(s)": [
        "Panel"
    ],
    "Document Summary": "FDA 510(k) summary for ETERBIO Fentanyl/Norfentanyl Rapid Test and Home Test for qualitative detection of fentanyl and norfentanyl in urine using immunoassay technology",
    "Indications for Use Summary": "Intended for qualitative, preliminary detection of fentanyl and norfentanyl in human urine as a screening test; confirmation by specific chemical methods such as GC/MS or LC/MS is recommended",
    "fda_folder": "Toxicology"
}